TNGX
Tango Therapeutics, Inc.
Biotechnology · Healthcare · United States
22.72
close · 2026-10-30
value
75
cheaper than peers75
quality
63
stronger fundamentals63
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -4.8% | 76 |
| cash flow yield, 1 year ago | -3.5% | 74 |
| cash flow yield, 2 years ago | -3.1% | 72 |
| earnings yield, 1 year ago | -5.2% | 71 |
| earnings yield, 3 years ago | -5.4% | 71 |
| cash flow yield, 3 years ago | -3.0% | 69 |
| earnings yield, latest year | -3.8% | 67 |
| cash flow yield, latest year | -3.7% | 66 |
| price to book | 3.73× | 46 |
| price to sales | 67.22× | 18 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 8.4% | 65 |
| return on equity | -38.4% | 62 |
| operating margin | -206.2% | 45 |
3 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$68.2M |
| employees | 137 |
| first trade | 2020-09-03 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.87 | -1.19 | -1.08 | -1.23 |
| free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M |
| net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M |
| revenue | $62.4M | $42.1M | $36.5M | $24.9M |